Clinical Outcomes and Characterisation of the Autologous Adipose Tissue Harvested With Superficial Enhanced Fluid Fat Injection Method for Treatment of Diabetic Foot Ulcer Undergoing Minor Amputation ( SEFFIDiFA Trial)
Klinische Ergebnisse und Charakterisierung von autologem Fettgewebe, gewonnen mit der SEFFI-Methode, zur Behandlung des diabetischen Fußulkus nach kleiner Amputation (SEFFIDiFA-Studie)
International Wound Journal · 2025-11 · 22 (11)
DOI: 10.1111/iwj.70784 ↗Auf einen Blick
In einer prospektiven, einarmigen Kohortenstudie heilten 55 % der Stümpfe 6 Monate nach kleiner Amputation und ASC-Injektion vollständig. Die mediane Heilungszeit betrug 69 Tage.
Fragestellung
Wie wirksam und sicher ist mit SEFFI gewonnenes Fettgewebe mit adiposären Stammzellen nach kleiner Amputation bei diabetischem Fußulkus?
Methode
Prospektive, einarmige, beobachtende Kohortenstudie; 6-monatige Nachbeobachtung mit monatlichen Kontrollen.
Ergebnisse
40 von 256 gescreenten Patient:innen wurden eingeschlossen. Nach 6 Monaten waren 55 % der behandelten Stümpfe vollständig geheilt; mediane Heilungszeit 69 Tage. Technischer Erfolg in allen Fällen ohne gerätebezogene Komplikationen.
Einschränkungen
Einarmiges Design ohne Vergleichsgruppe.
Schlussfolgerung der Autor:innen
Die SEFFIDiFA-Studie zeigte eine vielversprechende Heilungswahrscheinlichkeit von 69 % 6 Monate nach der Amputation. Der minimalinvasive Ansatz war mit höherer Heilungsrate und wenigen Komplikationen verbunden.
Kernaussagen
- 55 % vollständige Heilung nach 6 Monaten
- Mediane Heilungszeit: 69 Tage
- Kein gerätebezogener Komplikationsfall
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Wound Journal, online erschienen am 14.11.2025. Verfasst von Nicola Leone und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, M…. Hauptthemen laut MEDLINE: Diabetic Foot, Amputation, Surgical, Wound Healing, Adipose Tissue. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Diabetic foot ulcers (DFUs) are severe complications of diabetes that often lead to major amputations. Despite care advancements, approximately 50% of minor amputations do not heal, resulting in major amputations and increased mortality. This study evaluated the effectiveness of adipose‐derived stem cells (ASCs) obtained through superficial enhanced fluid fat injection (SEFFI) in improving healing rates after minor amputations in DFUs. It was a prospective, single‐arm, observational cohort study. The patients were monitored for half a year using monthly assessments. The primary endpoint was the healing rate of the amputation stumps after minor amputations coupled with ASC injections. Secondary endpoints included safety, feasibility, adverse events and analysis of variables associated with healing including the analysis of the injected mesenchymal adipose stem cell populations. Of the 256 screened patients, 40 were enrolled. At 6 months, 55% of the treated stumps had healed completely. The median healing time was 69 days. Technical success was achieved in all cases without device‐related complications. Multivariable Cox models identified haemodialysis, opioid use and the injected number of CD45 ‐positive cells as risk factors for healing failure. CD73 expression was positively associated with healing. The SEFFIDiFA trial demonstrated a promising 69% healing probability at 6 months post‐amputation. This minimally invasive approach showed a higher healing rate with fewer complications. This study supports the potential of ASCs in enhancing wound healing in DFUs and highlights the importance of CD73 expression for successful outcomes. Further research is warranted to validate these findings and optimise the technique.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Vascular Surgery, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy.
- Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
- Center for Genomic Research, University of Modena and Reggio Emilia, Modena, Italy.
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
ORCID-Profile: Mattia Migliari, Livio Casarini
Zitieren
APA
Leone, N., Andreoli, F., Migliari, M., Guerra, F., Sperduti, S., Casarini, L., Silingardi, R., & Gennai, S. (2025). Clinical Outcomes and Characterisation of the Autologous Adipose Tissue Harvested With Superficial Enhanced Fluid Fat Injection Method for Treatment of Diabetic Foot Ulcer Undergoing Minor Amputation ( SEFFIDiFA Trial). International Wound Journal, 22(11). https://doi.org/10.1111/iwj.70784
Vancouver
Leone N, Andreoli F, Migliari M, Guerra F, Sperduti S, Casarini L, et al. Clinical Outcomes and Characterisation of the Autologous Adipose Tissue Harvested With Superficial Enhanced Fluid Fat Injection Method for Treatment of Diabetic Foot Ulcer Undergoing Minor Amputation ( SEFFIDiFA Trial). International Wound Journal. 2025;22(11). doi:10.1111/iwj.70784
BibTeX
@article{Leone2025,
author = {Leone, Nicola and Andreoli, Francesco and Migliari, Mattia and Guerra, Federica and Sperduti, Samantha and Casarini, Livio and Silingardi, Roberto and Gennai, Stefano},
title = {Clinical Outcomes and Characterisation of the Autologous Adipose Tissue Harvested With Superficial Enhanced Fluid Fat Injection Method for Treatment of Diabetic Foot Ulcer Undergoing Minor Amputation ( SEFFIDiFA Trial)},
journal = {International Wound Journal},
year = {2025},
volume = {22},
number = {11},
doi = {10.1111/iwj.70784}
}
EUVIMED